Plasma Arginine Profiling for Personalized Cancer Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current arginine deprivation therapies, such as those using pegylated arginine deiminase (ADI-PEG 20), face challenges with resistance development and limited treatment windows due to cellular pathways activating resistance to apoptosis, necessitating improved therapeutic strategies.
Innovation Solution
The method involves determining plasma arginine levels to predict patient response to arginine deprivation therapy and tailoring treatment regimes using agents like pegylated rADI, DFMO, rADI, rArg, rADC, or combinations, along with anti-cancer agents like FOLFOX, docetaxel, cisplatin, pembrolizumab, based on plasma arginine levels to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If arginine deprivation therapy is administered to treat auxotrophic cancers, then therapeutic effect is improved, but resistance develops through ASS1 reactivation
Solution Approach 1:
The patent measures plasma arginine levels before initiating arginine deprivation therapy to identify patients who are most likely to respond. This preliminary assessment prevents wasting treatment on patients who will develop resistance, thereby maintaining therapeutic efficacy while avoiding the resistance problem altogether in non-responsive patients.
Solution Approach 2:
The patent uses plasma arginine level measurements as a feedback mechanism to monitor treatment response. By continuously assessing arginine levels, the therapy can be adjusted to maintain effectiveness while detecting early signs of resistance development, allowing for timely intervention or treatment modification.
2Duration of action of moving object
If prolonged arginine deprivation therapy is administered, then treatment window is extended, but cellular pathways activate resistance to apoptosis
Solution Approach 1:
The patent performs baseline plasma arginine level measurement before starting prolonged therapy to identify patients who will benefit from extended treatment. This preliminary screening ensures that only patients with favorable baseline characteristics undergo prolonged therapy, preventing the activation of apoptosis resistance pathways in patients who would not respond anyway.
Solution Approach 2:
The patent employs ongoing plasma arginine level monitoring during prolonged therapy to detect changes that may indicate emerging apoptosis resistance. This feedback allows for early termination or modification of treatment before resistance pathways become fully activated, maintaining both extended treatment window and therapeutic reliability.
3Reliability
If personalized treatment based on plasma arginine levels is implemented, then therapeutic efficacy is optimized, but measurement and monitoring complexity increases
Solution Approach 1:
The patent utilizes plasma arginine level measurements that can be obtained through routine clinical laboratory techniques. The body's natural arginine metabolism provides the measurement substrate, requiring only standard blood draws and analysis. This self-service approach allows personalized treatment optimization without adding significant complexity to the measurement process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for personalized treatment strategies that improve overall survival in cancer patients by optimizing arginine deprivation therapy, extending median survival times in response to specific plasma arginine thresholds.
Implementation Method 1
arginine deiminase (ADI), a microbial enzyme from mycoplasma that exhibits high affinity to arginine and catalyzes arginine to citrulline and ammonia
Data Source
AI summary
A method for providing a prediction as to whether a subject with a cancer exhibits a beneficial response to arginine deprivation therapy including determining the plasma level of arginine in the subject, followed by administering to the subject an arginine deprivation therapy alone or in combination with an anti-cancer agent based on the determined plasma level of arginine. According to some embodiments of the present disclosure, the anti-cancer agent is selected from the group consisting of FOLFOX, docetaxel, cisplatin, pemetrexed, pembrolizumab, and a combination thereof.